 Oragenics Inc NYSE: OGEN has initiated a hamster challenge study to evaluate the immunogenicity and viral load reduction impact of its COVID-19 vaccine candidate. Related Content: Oragenicss New Preclinical Data Supports Its Approach For COVID-19 Vaccine Development. 